Ubs Group Ag Pro Qr Therapeutics N.V. Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Ubs Group Ag holds 94,550 shares of PRQR stock, worth $207,064. This represents 0.0% of its overall portfolio holdings.

Number of Shares

94,550

Previous 1,143,835 91.73%

Holding current value

$207,064

Previous $2.33 Million 91.47%

% of portfolio

0.0%

Previous 0.0%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	SELL	$1.89 - $2.48 $1.98 Million - $2.6 Million	-1,049,285 Reduced 91.73%	94,550 $199,000
Q2 2025 Aug 14, 2025	SELL	$1.12 - $2.16 $720,399 - $1.39 Million	-643,214 Reduced 35.99%	1,143,835 $2.33 Million
Q1 2025 May 13, 2025	SELL	$1.33 - $2.77 $695,591 - $1.45 Million	-523,001 Reduced 22.64%	1,787,049 $2.38 Million
Q4 2024 Feb 14, 2025	BUY	$1.81 - $4.49 $4.18 Million - $10.4 Million	2,307,150 Added 79556.9%	2,310,050 $6.31 Million
Q3 2024 Nov 14, 2024	SELL	$1.64 - $2.24 $40,419 - $55,207	-24,646 Reduced 89.47%	2,900 $5,000

Q2 2024 Aug 13, 2024	BUY	$1.65 - $2.39 $37,250 - $53,956	22,576 Added 454.25%	27,546 $45,000
Q1 2024 May 13, 2024	BUY	$1.89 - $2.85 $2,022 - $3,049	1,070 Added 27.44%	4,970 $11,000
Q4 2023 Feb 09, 2024	SELL	$1.15 - $2.21 $7,065 - $13,578	-6,144 Reduced 61.17%	3,900 $7,000
Q3 2023 Nov 09, 2023	BUY	$1.3 - $1.77 $6,971 - $9,492	5,363 Added 114.57%	10,044 $13,000
Q2 2023 Aug 11, 2023	BUY	$1.62 - $2.32 $1,751 - $2,507	1,081 Added 30.03%	4,681 $7,000
Q1 2023 May 12, 2023	BUY	$1.99 - $3.66 $1,305 - $2,400	656 Added 22.28%	3,600 $7,000
Q4 2022 Feb 08, 2023	SELL	$0.8 - $3.7 $1,723 - $7,969	-2,154 Reduced 42.25%	2,944 $10,000
Q3 2022 Nov 10, 2022	BUY	$0.74 - $0.89 $3,772 - $4,537	5,098 New	5,098 $4,000
Q1 2022 May 16, 2022	SELL	$0.9 - $8.39 $75,894 - $707,503	-84,327 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$6.58 - $8.44 $64,411 - $82,619	-9,789 Reduced 10.4%	84,327 $675,000
Q3 2021 Nov 15, 2021	BUY	$5.16 - $8.47 $165,651 - $271,912	32,103 Added 51.77%	94,116 $787,000
Q2 2021 Aug 13, 2021	SELL	$5.75 - $7.59 $164,461 - $217,089	-28,602 Reduced 31.56%	62,013 $418,000
Q1 2021 May 12, 2021	SELL	$4.14 - $9.22 $1.58 Million - $3.52 Million	-381,488 Reduced 80.81%	90,615 $599,000
Q4 2020 Feb 11, 2021	SELL	$3.58 - $4.85 $22,274 - $30,176	-6,222 Reduced 1.3%	472,103 $1.98 Million
Q3 2020 Nov 12, 2020	SELL	$4.79 - $6.3 $18,877 - $24,828	-3,941 Reduced 0.82%	478,325 $2.29 Million
Q2 2020 Jul 31, 2020	SELL	$4.5 - $6.53 $1,543 - $2,239	-343 Reduced 0.07%	482,266 $2.93 Million
Q1 2020 May 01, 2020	SELL	$5.25 - $9.9 $132,704 - $250,242	-25,277 Reduced 4.98%	482,609 $2.65 Million
Q4 2019 Feb 14, 2020	BUY	$5.84 - $10.51 $328,167 - $590,588	56,193 Added 12.44%	507,886 $5.03 Million
Q3 2019 Nov 14, 2019	SELL	$5.76 - $9.44 $86,929 - $142,468	-15,092 Reduced 3.23%	451,693 $2.6 Million
Q2 2019 Aug 14, 2019	BUY	$9.1 - $15.55 $4.25 Million - $7.26 Million	466,785 New	466,785 $4.25 Million
Q1 2019 May 14, 2019	SELL	$12.5 - $18.48 $35.7 Million - $52.7 Million	-2,854,433 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$15.25 - $22.4 $43.5 Million - $63.9 Million	2,854,207 Added 1262923.5%	2,854,433 $45 Million
Q3 2018 Nov 14, 2018	BUY	$6.45 - $21.6 $1,457 - $4,881	226 New	226 $4,000
Q2 2018 Aug 14, 2018	SELL	$2.95 - $7.45 $8,546 - $21,582	-2,897 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$2.9 - $3.5 $2,908 - $3,510	1,003 Added 52.96%	2,897 $9,000
Q4 2017 Feb 14, 2018	SELL	$2.8 - $4.8 $1,450 - $2,486	-518 Reduced 21.48%	1,894 $6,000
Q3 2017 Nov 14, 2017	BUY	$4.35 - $6.45 $2,810 - $4,166	646 Added 36.58%	2,412 $12,000
Q2 2017 Aug 14, 2017	BUY	N/A	1,766	1,766 $9,000

Others Institutions Holding PRQR

# of Institutions

Shares Held

38.3M

Call Options Held

Put Options Held

View Full List

About ProQR Therapeutics N.V.

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $156M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

More about PRQR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account